ML-132, identified by its CAS number 1230628-71-3, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is primarily recognized as a selective inhibitor of the protein kinase CK2, which plays a crucial role in various cellular processes, including cell proliferation and survival. The inhibition of CK2 has implications in cancer research, as it may help in the development of targeted therapies for certain malignancies. ML-132 exhibits a specific binding affinity for CK2, which distinguishes it from other kinase inhibitors. Its chemical structure includes functional groups that contribute to its biological activity and solubility profile. In preclinical studies, ML-132 has demonstrated efficacy in inhibiting tumor growth, making it a candidate for further investigation in drug development. However, detailed pharmacokinetic and toxicological profiles are essential for understanding its safety and efficacy in clinical settings. As research progresses, ML-132 may provide insights into novel therapeutic strategies against cancer and other diseases associated with dysregulated kinase activity.

ML-132

1230628-71-3: ML-132, identified by its CAS number 1230628-71-3, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is primarily recognized as a selective inhibitor of the protein kinase CK2, which plays a crucial role in various cellular processes, including cell proliferation and survival. The inhibition of CK2 has implications in cancer research, as it may help in the development of targeted therapies for certain malignancies. ML-132 exhibits a specific binding affinity for CK2, which distinguishes it from other kinase inhibitors. Its chemical structure includes functional groups that contribute to its biological activity and solubility profile. In preclinical studies, ML-132 has demonstrated efficacy in inhibiting tumor growth, making it a candidate for further investigation in drug development. However, detailed pharmacokinetic and toxicological profiles are essential for understanding its safety and efficacy in clinical settings. As research progresses, ML-132 may provide insights into novel therapeutic strategies against cancer and other diseases associated with dysregulated kinase activity.

<p>ML132 is a dichroic compound that has been shown to have inhibitory effects on the acid complex in cardiac cells. It also has biochemical properties that are similar to those of a known inhibitor of the mitochondrial enzyme, aconitase. ML132 has been shown to be effective in reducing blood pressure and increasing the autophagy rate in animals. This drug may also have an effect on retinal tissue because it is highly soluble in organic solvents. The optical system used for this research was a sectioning system with microlenses and was used to study the effects of ML132 on neurons from rats.</p>

ML132

<p>ML132 is an effective and selective inhibitor of caspase 1 (IC50: 0.316 nM).</p>

CAS 1230628-71-3

ML-132

ML132

Ref: 3D-FZB62871

ML132

Ref: TM-T16105